Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Operating Expenses (2023 - 2025)

Historic Operating Expenses for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$2.6 million.

  • BioLineRx's Operating Expenses rose 3552.47% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 3247.84%. This contributed to the annual value of -$15.5 million for FY2024, which is 1783.95% up from last year.
  • Per BioLineRx's latest filing, its Operating Expenses stood at -$2.6 million for Q3 2025, which was up 3552.47% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Operating Expenses ranged from a high of -$2.5 million in Q2 2025 and a low of -$5.3 million during Q4 2023
  • Over the past 3 years, BioLineRx's median Operating Expenses value was -$3.9 million (recorded in 2024), while the average stood at -$3.8 million.
  • As far as peak fluctuations go, BioLineRx's Operating Expenses surged by 641.27% in 2024, and later surged by 3552.47% in 2025.
  • Over the past 3 years, BioLineRx's Operating Expenses (Quarter) stood at -$5.3 million in 2023, then grew by 28.79% to -$3.8 million in 2024, then surged by 32.56% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$2.5 million for Q2 2025, and -$2.6 million during Q1 2025.